<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study provides up-to-date and detailed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survival estimates of German patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL, International Statistical Classification of Diseases 10th Revision [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-10] codes C82-C85) based on data from 11 cancer registries </plain></SENT>
<SENT sid="1" pm="."><plain>Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology </plain></SENT>
<SENT sid="2" pm="."><plain>Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period </plain></SENT>
<SENT sid="3" pm="."><plain>Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1% </plain></SENT>
<SENT sid="4" pm="."><plain>Survival decreased with age from 81.7% at age 15-49 to 46.5% at age 75+ </plain></SENT>
<SENT sid="5" pm="."><plain>Survival in the US was 75.3% at age 15-49 and 52% at age 75+ </plain></SENT>
<SENT sid="6" pm="."><plain>Survival was higher for women than for men, at 65.2% for women and 60.7% for men </plain></SENT>
<SENT sid="7" pm="."><plain>Survivals for diffuse B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the two most common subtypes of NHL, were 57.3% and 77.5%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Between 2002 and 2006, overall 5-year relative survival increased by 5.3 percentage points </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that survival for NHL is increasing in Germany in recent years </plain></SENT>
<SENT sid="10" pm="."><plain>Survival was higher in Germany than in the US for patients aged 15-49 but lower for older patients </plain></SENT>
</text></document>